Valuation: Autolus Therapeutics plc

Market Cap 386M 339M 315M 289M 543M 37.16B 552M 3.74B 1.46B 18.27B 1.45B 1.42B 63.17B P/E 2026 *
-1.63x
P/E 2027 * -2.3x
Enterprise Value 346M 304M 283M 260M 488M 33.36B 495M 3.36B 1.31B 16.4B 1.3B 1.27B 56.7B EV / Sales 2026 *
2.69x
EV / Sales 2027 * 2.27x
Free-Float
3.32%
Yield 2026 *
-
Yield 2027 * -
1 day-4.61%
1 week+0.69%
Current month-9.38%
1 month-8.81%
3 months+0.69%
6 months-0.68%
Current year-27.14%
1 week 1.38
Extreme 1.38
1.54
1 month 1.38
Extreme 1.38
1.74
Current year 1.18
Extreme 1.175
2.07
1 year 1.18
Extreme 1.175
2.6
3 years 1.1
Extreme 1.105
7.45
5 years 1.1
Extreme 1.105
7.9
10 years 1.1
Extreme 1.105
53.24
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 53 01/09/2014
Chief Executive Officer 61 01/03/2016
Director of Finance/CFO 56 07/08/2023
Director TitleAgeSince
Chairman 61 01/10/2014
Director/Board Member 78 01/08/2014
Director/Board Member 71 01/03/2018
Date Insider Type Main position Quantity % Market Cap.
29/6/26 Free

Director

79,167 0.0477%
29/6/26 Free

Director

79,167 0.0477%
29/6/26 Free

Director

79,167 0.0477%
Change 5-day change 1-year change 3-year change Capi.($)
-4.61%+0.69%-42.46%-49.65% 386M
+0.63%-3.06%+16.50%-10.12% 66.74B
+1.23%+2.80%+38.09%+200.66% 53.32B
+10.08%+51.80%+51.80%+51.80% 48.12B
-1.32%-7.38%-57.37%-56.96% 38.25B
+0.78%-1.84%+53.73%-25.20% 29.85B
+0.84%+0.36%+67.62%+84.46% 23.51B
-5.17%-12.54%+58.33%-55.63% 21.45B
-1.21%+1.12%+0.90%+164.17% 19.97B
+1.31%+3.24%+81.47%+157.97% 16.47B
Average +0.26%-0.41%+26.86%+46.15% 31.81B
Weighted average by Cap. +1.48%+0.11%+28.98%+51.05%

Financials

2026 *2027 *
Net sales 129M 113M 105M 96.37M 181M 12.38B 184M 1.25B 487M 6.09B 483M 472M 21.05B 191M 168M 156M 143M 269M 18.39B 273M 1.85B 724M 9.04B 717M 701M 31.26B
Net income -242M -213M -198M -182M -341M -23.34B -347M -2.35B -918M -11.47B -910M -890M -39.67B -185M -162M -151M -138M -260M -17.79B -264M -1.79B -700M -8.75B -693M -678M -30.24B
Net Debt -39.53M -34.72M -32.29M -29.63M -55.67M -3.81B -56.53M -383M -150M -1.87B -148M -145M -6.47B 48.41M 42.52M 39.54M 36.29M 68.18M 4.66B 69.23M 470M 183M 2.29B 182M 178M 7.93B
Logo Autolus Therapeutics plc
Autolus Therapeutics plc is a United Kingdom-based early commercial-stage biopharmaceutical company developing programmed T cell therapies for the treatment of cancer and autoimmune diseases. The Company has an approved commercial product, AUCATZYL, for the treatment of adult patients with r/r B-ALL. Using a suite of proprietary and modular T cell programming technologies, it is also developing five programs in seven hematological and solid tumor indications and one autoimmune indication. It is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize target cells, break down their defense mechanisms and attack and eliminate these cells. Its product pipeline includes obe-cel (ALLCAR19), obe-cel (CAROUSEL), AUTO1/22 (CARPALL), AUTO4 (LibrA T1), AUTO6 (MAGNETO), AUTO5, AUTO8 (MCARTY) and AUTO9. AUTO4 and AUTO5 are two programmed T cell therapies for the treatment of peripheral T-cell lymphoma targeting TRBC 1 and TRBC 2.
Employees
753
Date Price Change Volume
24/07/26 USD 1.450 -4.61% 717,005
23/07/26 USD 1.520 +5.56% 970,694
22/07/26 USD 1.440 -1.71% 493,286
21/07/26 USD 1.465 +4.64% 879,129
20/07/26 USD 1.400 -2.78% 852,525
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
1.450USD
Average target price
8.550USD
Spread / Average Target
+489.66%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. AUTL Stock